Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension
(2007) In Blood Pressure 16(S2). p.25-30- Abstract
- Two first-line antihypertensive therapies for initiating treatment in hypertension were compared, the angiotensin-converting enzyme inhibitor (ACEI) zofenopril and the beta-blocker atenolol. The study was multi-centre and double-blind, and included 304 middle-aged to elderly patients with mild to moderate hypertension who were randomized to receive either zofenopril 30-60 mg once daily (od) or atenolol 50-100 mg od for 4 weeks with the possibility to an up-titration in non-responding patients. The higher dose level was then administered until 12 weeks after randomization. Blood pressures (BPs) were substantially reduced by either treatment, but after 4 weeks, the systolic and diastolic BP reductions were significantly greater (p < 0.05)... (More)
- Two first-line antihypertensive therapies for initiating treatment in hypertension were compared, the angiotensin-converting enzyme inhibitor (ACEI) zofenopril and the beta-blocker atenolol. The study was multi-centre and double-blind, and included 304 middle-aged to elderly patients with mild to moderate hypertension who were randomized to receive either zofenopril 30-60 mg once daily (od) or atenolol 50-100 mg od for 4 weeks with the possibility to an up-titration in non-responding patients. The higher dose level was then administered until 12 weeks after randomization. Blood pressures (BPs) were substantially reduced by either treatment, but after 4 weeks, the systolic and diastolic BP reductions were significantly greater (p < 0.05) with zofenopril (-15.6/-13.5 mmHg) compared with atenolol (-13.1/-11.8 mmHg). After 12 weeks and the possibility of dose up-titration, BP differences between treatments were no longer significant. However, control rates (sitting diastolic BP < 90 mmHg) for zofenopril remained significantly higher compared with atenolol. The number of subjects with adverse drug reactions possibly or probably related to the study medication was 14 (9.1 %) in the zofenopril group and 30 (20.8%) in the atenolol group (p=0.008). It is concluded that zofenopril as well as atenolol induces substantial reductions of diastolic BP in middle-aged to elderly patients with hypertension. However, the control rate when initiating antihypertensive therapy with zofenopril is higher than that for atenolol. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/654188
- author
- Nilsson, Peter LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adrenergic beta-Antagonists: adverse effects, Adrenergic beta-Antagonists: therapeutic use, Angiotensin-Converting Enzyme Inhibitors: adverse effects, Angiotensin-Converting Enzyme Inhibitors: therapeutic use, Atenolol: adverse effects, Atenolol: therapeutic use, Blood Pressure: drug effects, Captopril: adverse effects, Captopril: analogs & derivatives, Captopril: therapeutic use, Hypertension: drug therapy
- in
- Blood Pressure
- volume
- 16
- issue
- S2
- pages
- 25 - 30
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000250506600005
- pmid:18046976
- scopus:74249117410
- ISSN
- 0803-7051
- DOI
- 10.1080/08038020701561745
- language
- English
- LU publication?
- yes
- id
- 69c662dc-99a2-46b8-8b3c-2b1cca616552 (old id 654188)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/18046976?dopt=Abstract
- date added to LUP
- 2016-04-01 12:25:47
- date last changed
- 2022-03-29 00:46:21
@article{69c662dc-99a2-46b8-8b3c-2b1cca616552,
abstract = {{Two first-line antihypertensive therapies for initiating treatment in hypertension were compared, the angiotensin-converting enzyme inhibitor (ACEI) zofenopril and the beta-blocker atenolol. The study was multi-centre and double-blind, and included 304 middle-aged to elderly patients with mild to moderate hypertension who were randomized to receive either zofenopril 30-60 mg once daily (od) or atenolol 50-100 mg od for 4 weeks with the possibility to an up-titration in non-responding patients. The higher dose level was then administered until 12 weeks after randomization. Blood pressures (BPs) were substantially reduced by either treatment, but after 4 weeks, the systolic and diastolic BP reductions were significantly greater (p < 0.05) with zofenopril (-15.6/-13.5 mmHg) compared with atenolol (-13.1/-11.8 mmHg). After 12 weeks and the possibility of dose up-titration, BP differences between treatments were no longer significant. However, control rates (sitting diastolic BP < 90 mmHg) for zofenopril remained significantly higher compared with atenolol. The number of subjects with adverse drug reactions possibly or probably related to the study medication was 14 (9.1 %) in the zofenopril group and 30 (20.8%) in the atenolol group (p=0.008). It is concluded that zofenopril as well as atenolol induces substantial reductions of diastolic BP in middle-aged to elderly patients with hypertension. However, the control rate when initiating antihypertensive therapy with zofenopril is higher than that for atenolol.}},
author = {{Nilsson, Peter}},
issn = {{0803-7051}},
keywords = {{Adrenergic beta-Antagonists: adverse effects; Adrenergic beta-Antagonists: therapeutic use; Angiotensin-Converting Enzyme Inhibitors: adverse effects; Angiotensin-Converting Enzyme Inhibitors: therapeutic use; Atenolol: adverse effects; Atenolol: therapeutic use; Blood Pressure: drug effects; Captopril: adverse effects; Captopril: analogs & derivatives; Captopril: therapeutic use; Hypertension: drug therapy}},
language = {{eng}},
number = {{S2}},
pages = {{25--30}},
publisher = {{Taylor & Francis}},
series = {{Blood Pressure}},
title = {{Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension}},
url = {{http://dx.doi.org/10.1080/08038020701561745}},
doi = {{10.1080/08038020701561745}},
volume = {{16}},
year = {{2007}},
}